• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    89Bio Inc (NQ: ETNB )

    7.350 +0.040 (+0.55%)
    Streaming Delayed Price Updated: 12:35 PM EDT, Oct 10, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 156,398
    Open 7.210
    Bid (Size) 7.330 (38)
    Ask (Size) 7.360 (19)
    Prev. Close 7.310
    Today's Range 7.100 - 7.370
    52wk Range 6.575 - 16.63
    Shares Outstanding 75,480,884
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    89bio to Participate in the H.C. Wainwright 8th Annual MASH Investor Conference
    From 89bio, Inc.
    Via GlobeNewswire
    89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From 89bio, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -34.90%
    -34.90%
    1 Month
    -13.12%
    -13.12%
    3 Month
    -15.03%
    -15.03%
    6 Month
    -30.27%
    -30.27%
    1 Year
    -24.81%
    -24.81%

    More News

    Read More
    89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer
    From 89bio, Inc.
    Via GlobeNewswire
    ETNB Stock Earnings: 89bio Beats EPS for Q2 2024
    Via InvestorPlace
    ETNB Stock Earnings: 89bio Misses EPS for Q1 2024
    Via InvestorPlace
    89bio to Participate in Upcoming Investor Conferences
    From 89bio, Inc.
    Via GlobeNewswire
    89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From 89bio, Inc.
    Via GlobeNewswire
    89bio Appoints Francis Sarena as Chief Operating Officer
    From 89bio, Inc.
    Via GlobeNewswire
    89bio Reports Second Quarter 2024 Financial Results and Corporate Updates
    From 89bio, Inc.
    Via GlobeNewswire
    89bio Appoints Charles McWherter, Ph.D., to its Board of Directors
    From 89bio, Inc.
    Via GlobeNewswire
    89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From 89bio, Inc.
    Via GlobeNewswire
    89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From 89bio, Inc.
    Via GlobeNewswire
    What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday?
    Via Benzinga
    Madrigal, Akero, 89bio Tumble After Lilly's Weight-Loss Drug Tackles MASH
    Via Investor's Business Daily
    The Week Ahead: What's Next
    Via Talk Markets
    89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress
    From 89bio, Inc.
    Via GlobeNewswire
    89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis
    From 89bio, Inc.
    Via GlobeNewswire
    89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From 89bio, Inc.
    Via GlobeNewswire
    89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
    From 89bio, Inc.
    Via GlobeNewswire
    89bio to Participate in the BofA Securities 2024 Health Care Conference
    From 89bio, Inc.
    Via GlobeNewswire
    89bio to Host Key Opinion Leader Webinar on Pegozafermin’s Opportunity in Advanced MASH
    From 89bio, Inc.
    Via GlobeNewswire
    89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors
    From 89bio, Inc.
    Via GlobeNewswire
    89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From 89bio, Inc.
    Via GlobeNewswire
    89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis
    From 89bio, Inc.
    Via GlobeNewswire
    Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?
    Via The Motley Fool
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.